Immutep Stock Price, News & Analysis

Immutep (ASX: IMM; NASDAQ: IMMP) announced it has secured a cash rebate of A$986,286 (~US$659,303) from the Australian Federal Government's R&D tax incentive program for eligible R&D activities in the 2021 fiscal year, particularly for its TACTI-002 clinical study involving eftilagimod alpha (efti). This follows a previous EU tax incentive of €1,804,341 (~US$1,862,143). The funds will support ongoing clinical trials, with cash flow expected to last into the first half of 2024.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has reported encouraging clinical results from its Phase II TACTI-002 trial. The overall response rate (ORR) for the combination therapy of eftilagimod alpha (efti) and KEYTRUDA® in treating first-line non-small cell lung cancer (NSCLC) increased to 40.4%, with notable improvements across all PD-L1 expression groups. Median duration of response was 21.6 months, showing efficacy irrespective of PD-L1 status. The trial, which included 114 patients, demonstrated a favorable safety profile, with only 9.6% discontinuation due to adverse effects.

Immutep Limited (NASDAQ: IMMP) announced promising early results from the INSIGHT-003 trial, evaluating its lead product candidate, eftilagimod alpha (efti), in combination with anti-PD-1 therapy and chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC). The trial reported an Objective Response Rate (ORR) of 72.7% and a Disease Control Rate (DCR) of 90.9%, indicating strong efficacy, particularly among patients with low PD-L1 expression. The combination therapy demonstrated a favorable safety profile with minimal adverse effects.

Immutep Limited has announced the grant of two new patents for cancer treatment in Japan and South Korea. These patents protect combination therapies involving eftilagimod alpha (efti) and various chemotherapy agents, with an expiry date set for December 19, 2034. This follows the earlier grant of related patents across the US, Europe, China, and Australia. CEO Marc Voigt emphasized the importance of these patents in strengthening the company’s intellectual property and supporting the ongoing INSIGHT-003 clinical trial, with initial efficacy data expected at SITC 2022.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced its late-breaking abstract showcasing efficacy results for eftilagimod alpha in combination with pembrolizumab for non-small cell lung cancer (NSCLC) at the SITC 2022 Annual Meeting. Selected from over 1,500 submissions, it will be presented on November 8, 2022. A webcast on November 10, 2022, will discuss the abstract and Company updates. Additional data from the TACTI-002 Phase II trial will also be presented, with implications for ongoing and future cancer therapies.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) will present new clinical data for eftilagimod alpha in combination with pembrolizumab at the SITC Annual Meeting 2022. The oral presentation, scheduled for November 10, 2022, will focus on the TACTI-002 Phase II trial results involving 1st line non-small cell lung cancer (NSCLC) patients. Efti acts as an APC activator, aiming to enhance immune responses. The meeting will take place in Boston and virtually from November 8-12, 2022, with further details on the presentations to be available online.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced its CEO, Marc Voigt, will present at two investor conferences. The Bell Potter Healthcare Conference is scheduled for November 9, 2022, from 10:00am – 10:30am AEDT, followed by the 13th Annual Jefferies London Healthcare Conference on November 17, 2022, from 1:30pm – 2pm UTC. A live webcast of the Jefferies conference will be available on the company's website. Immutep focuses on developing LAG-3 immunotherapies for cancer and autoimmune diseases.

Immutep Limited has announced positive progress in its Phase IIb TACTI-003 trial, with the Independent Data Monitoring Committee recommending the continuation of the trial with no modifications. The trial evaluates eftilagimod alpha in combination with KEYTRUDA® for treating head and neck squamous cell carcinoma. Currently, 34% of the 154 patients have been recruited, and the FDA has granted Fast Track designation for this combination therapy, facilitating quicker clinical development and potential approval.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced its clinical development strategy focusing on eftilagimod alpha (efti) for treating non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), and metastatic breast cancer (MBC). Positive interim data from the TACTI-002 trial in NSCLC showed favorable results compared to standard chemotherapy. Additionally, the FDA granted Fast Track designation for efti in 1st line NSCLC. The company holds a strong cash position of $73.9 million, extending its financial runway into early 2024.